Peer-reviewed article
An updated safety review of the current drugs for managing ADHD in children
Erika Ryst, Ann Catherine Childress ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a medical literature review of the safety profile of pharmaceutical treatments for ADHD in children and adolescents. It examines clinical trials, systematic reviews, and safety data on stimulant and non-stimulant medications, covering adverse effects such as cardiovascular impacts, seizures, growth effects, and psychiatric outcomes. The review concludes that available treatments have favorable efficacy and safety profiles, though some patients remain unresponsive to current options.
Key points
- ADHD is a prevalent condition causing significant impairment when untreated
- Safety review covers cardiovascular effects, seizures, growth impact, depression, suicidal ideation, substance use disorders, psychosis, and tics
- Available pharmacologic treatments have favorable efficacy, safety and tolerability for many patients
- Multiple stimulant and non-stimulant formulations exist but some individuals do not tolerate them or achieve satisfactory improvement
- Ongoing research targets dopamine, norepinephrine, and novel receptors in ADHD treatment
Limitations
This is a literature review focused on medication safety rather than a primary research study evaluating outcomes. It does not assess the effectiveness of treatments for improving children's well-being or development beyond symptom management, nor does it examine non-pharmacological interventions or long-term developmental impacts.
Abstract
INTRODUCTION: Attention-Deficit/Hyperactivity Disorder (ADHD) is a highly prevalent condition that causes persistent problems with attention and/or hyperactivity-impulsivity and often results in significant impairment when left untreated. Medications for this disorder continue to evolve and provide new treatment options. Ongoing review of related medication safety and tolerability remains an important task for prescribers. AREAS COVERED: This manuscript provides an updated safety review of medications used to treat ADHD in children and adolescents. PubMed and OneSearch online databases were utilized to search for literature relevant to the topic of ADHD medications and safety. Clinical trials of medications used to treat ADHD, systematic reviews and meta-analyses, and articles covering specific safety issues (adverse or unfavorable events) such as cardiovascular effects, seizures, impact on growth, depression, suicidal ideation, substance use disorders, psychosis, and tics are described. EXPERT OPINION: Available pharmacologic treatments for ADHD have favorable efficacy, safety and tolerability and allow many patients to achieve significant improvement of their symptoms. Despite the availability of multiple stimulant and non-stimulant formulations, some individuals with ADHD may not tolerate available medications or attain satisfactory improvement. To satisfy unmet clinical needs, ADHD pharmaceutical research with stimulant and nonstimulant formulations targeting dopamine, norepinephrine, and novel receptors is ongoing.